Basel, Switzerland (ots/PRNewswire) - - For non US or non UK Media Only - Oral Chemotherapy Tablet Option Reduces the Time Patients Need to Spend in the Hospital Data recently published in the New England Journal of Medicine confirm oral chemotherapy tablet Xeloda (capecitabine) as a first-line ...
Toronto (ots/PRNewswire) - - President of cbm, Prof. Allen Foster Announces That cbm Has Expanded its Areas of Work to Include All Persons With Disability, Not Just Persons With Visual Loss. For the past 100 years, cbm previously known as Christoffel Blinden Mission, and Christian Blind Mission, has worked to prevent and treat blindness and provide education and rehabilitation services for persons with visual loss. "The organization has decided that its ...
Lyon, France (ots/PRNewswire) - - Exclusive Agreement for Rabies Monoclonal Antibodies to Fight Fatal Disease Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has signed an exclusive collaboration and commercialization agreement with Crucell N.V. (Euronext, NASDAQ: CRXL) for Crucell's rabies monoclonal antibodies ...
Malvern, Pennsylvania (ots/PRNewswire) - Solstice Neurosciences, Inc. ("Solstice") announced the appointment of Dennis L. Smith as President and Chief Executive Officer. He will also continue to serve as Chairman to its Board of Directors. Mr. Smith brings unique specialty pharmaceutical ...
Centre Hospitalier de l'Universite de Montreal (CHUM)
Montreal, Canada (ots/PRNewswire) - The Centre hospitalier de l'Université de Montréal (CHUM) announces the beginning of a phase II randomized double-blind trial with the potential of providing a therapeutic alternative after a first acute myocardial infarction. One patient has already undergone this technique, ...
Basel (ots/PRNewswire) - - Avastin Offers Patients the Chance to Live Twice as Long Without Their Disease Advancing Avastin (bevacizumab), Roche's innovative anti-cancer drug, was approved today in Europe for the first-line treatment of patients with advanced renal cell cancer (RCC) in combination with interferon (IFN), the current standard of care[*]. ...
Mississauga, Canada (ots/PRNewswire) - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) and Grupo Ferrer Internacional, S.A. ("Ferrer"), a leading European pharmaceutical and medical devices company, today announced the receipt of initial orders for Vasogen's Celacade(TM) System in Germany. Celacade, a first-in-class therapy, is the only CE Mark approved product that ...
Siemens Medical Solutions Diagnostics
Deerfield, Illinois (ots/PRNewswire) - - Third-Generation TRAb Assay Delivers Unprecedented Specificity for Diagnosing Graves' Disease Siemens Medical Solutions Diagnostics (www.siemens.com/diagnostics) announced that it has signed an agreement with KreLo GmbH Medical Diagnostics for the rights to develop ...
San Antonio, Texas (ots/PRNewswire) - - Roche in Collaboration With Genentech Commit to Large Phase III Adjuvant Clinical Programme Set to Unlock Avastin's Potential in Early Breast Cancer According to new phase II study data, Avastin (bevacizumab) can proceed to be tested after breast cancer surgery in combination with anthracycline containing regimens. ...
San Antonio, Texas (ots/PRNewswire) - - Studies Show Breast Cancer Patients Benefit From Continued Use of Herceptin After Progression of the Disease Data presented at the 30th Annual San Antonio Breast Cancer Symposium confirm that Herceptin is the standard of care for women with HER2-positive breast ...
San Antonio, Texas (ots/PRNewswire) - New data presented today at the San Antonio Breast Cancer Symposium (SABCS) show that adding Xeloda (capecitabine) to the current gold standard combination of Herceptin (trastuzumab) and docetaxel allows patients with advanced HER2-positive breast cancer to live, on average 5 ...
Basel, Switzerland (ots/PRNewswire) - - Physicians Will be Able to Prescribe MabThera With Their Preferred Chemotherapy Regimen as Initial Treatment Roche announced today that the European Union's Committee on Human Medical Products (CHMP) has given a positive recommendation for extension of the MabThera ...
Basel, Switzerland (ots/PRNewswire) - Roche has received positive recommendations for the Marketing Authorisation extensions for both its anti-angiogenic agent Avastin (bevacizumab) and oral chemotherapy Xeloda (capecitabine) from the European Committee for Medicinal Products for Human Use (CHMP). The ...
Baar (ots) - "The Albanian Council of Ministers has approved Decision No. 796 regarding the approval of production sharing for exploration, development and production of hydrocarbons on onshore Albania, in Blocks A-B and D-E, between the Ministry of Economy, Trade and Energy, represented by the National Agency of ...
Malvern, Pennsylvania (ots/PRNewswire) - - Solstice Neurosciences, Inc. Launches a Self-Guided Lesson as Prep for In-Person Workshops In recognition that physician comfort and knowledge with techniques around botulinum toxin injections lead to the best results for patients with cervical dystonia (CD), Solstice Neurosciences, Inc. (Solstice) has created ...
Basel, Switzerland (ots/PRNewswire) - - Higher Response Rates Seen in Untreated and Relapsed CLL Patients For non-US media only Abstract Number: 626 Abstract Number: 752 Early results from two phase II trials tracking the outcome of patients with chronic lymphocytic leukaemia (CLL) who were treated with the innovative cancer therapy MabThera ...
Calgary, Canada (ots/PRNewswire) - - New Class of ApoA-I/HDL Drugs to Reverse Atherosclerosis Enters the Clinic Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has received approval by the US Food and Drug Administration (FDA) to initiate a Phase 1a clinical trial of oral RVX-208 in the USA. RVX-208 is a novel first-in-class small ...
Basel, Switzerland (ots/PRNewswire) - - Phase II Results Suggest Avastin Can be Used in Curative Setting Date Experts attending the 30th San Antonio Breast Cancer Symposium (SABCS) December 13-16, will be amongst the first to hear new data that highlight further advances in the treatment of breast ...
Copenhagen (ots/PRNewswire) - - Attention Medical Trade Press Only - Further Study Demonstrates Efficacy and Tolerability of Escitalopram in Premenstrual Dysphoric Disorder New data released today reinforces the superiority of escitalopram compared to duloxetine in the acute treatment of depression ...
Toronto (ots/PRNewswire) - "Governments need to recognize the rights and needs of people with disabilities," says Prof. Allen Foster, President of CBM on the International Day of Disabled Persons. Millennium Development Goals set out by the United Nations will not be achieved without the inclusion of the disabled in development programming states Foster. CBM is a leading advocate for the human rights of ...
Calgary, Canada, November 29 (ots/PRNewswire) - - ApoA-I Technology is Recognized for its Ability to Transform the Treatment of Cardiovascular Disease Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today that the World Economic Forum has selected Resverlogix as a winner of the very prestigious Technology Pioneer Award in recognition of ...
Leipzig, Germany, November 29 (ots/PRNewswire) - - Ophthalmic Clinic in Germany First in Europe To Treat Patients With New Focused Radiation Therapy NeoVista, Inc. announced today that the first European patient has been treated in the company's pivotal global clinical trial for its novel beta radiation epiretinal therapy for the wet form of age-related ...
Collegeville, Pennsylvania, November 26 (ots/PRNewswire) - - TORISEL Extends Median Overall Survival vs. Interferon-Alpha Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the European Commission has approved TORISEL(TM) (temsirolimus) for the first-line treatment of patients ...
Toronto, November 22 (ots/PRNewswire) - "CBM urgently needs help for the most vulnerable people affected by the recent flooding in Bangladesh," says Prof. Allen Foster President of CBM. The latest report says the death toll in the fiercest cyclone to hit Bangladesh's southern and southwestern coastal area in over 130 years has climbed to over 2,300. "Our staff and partners on the ground are reporting that many people with disabilities living in poverty are ...
Basel, Switzerland, November 20 (ots/PRNewswire) - - Annals of Oncology Paper Suggests That Oral Agents Such as Xeloda, Which are Proven to be Equally Effective and Have a Tolerable Side Effect Profile, Should Replace Traditional Intravenous Chemotherapy A review paper in Annals of Oncology now ...
Amsterdam, November 19 (ots/PRNewswire) - Kiadis Pharma announced today that it has agreed to provide Rhitol during a limited period of time to requesting physicians participating in the ongoing phase I/II trial. The Rhitol phase I/II trial is closed for enrolment to treat new patients and is expected to complete ...
Basel, Switzerland, November 16 (ots/PRNewswire) - - Avastin Offers Patients the Chance to Live Twice as Long Without Their Disease Advancing Roche announced today that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for Avastin (bevacizumab) for ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 09.11.2007 Pfaeffikon SZ, 9 November 2007 --- The Board of Directors of shaPE Capital AG has decided to simplify its management structure by replacing the full-time CEO position with a part-time Company Secretary function. In this context, ...
Cape Town, South Africa, November 9 (ots/PRNewswire) - - Technology Transfer Creates Sustainable Solution to Treat One of the World's Oldest and Deadliest Diseases During the annual meeting of the International Union Against Tuberculosis and Lung Disease (IUATLD), The Lilly MDR-TB Partnership brought ...
Beijing, November 8 (ots/PRNewswire) - - Research Shows the New Test is Accurate, Simple to Run and Requires Minimal Resources Research demonstrating the potential of a special type of HPV test developed by QIAGEN with support from PATH -- a non-profit global health organization -- to reduce the incidence ...